{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.3.1', 'Inclusion Criteria', '8.', 'Women of childbearing potential must have a negative urine pregnancy test at', 'Baseline/Day 1. Subjects who are sexually active with a non-vasectomized male', 'partner must and agree to use 2 reliable forms of contraception during the trial and', 'continue for 180 days after the last dose of study drug. One of the 2 forms of', 'contraception is recommended to be hormonal, such as an oral contraceptive. Hormonal', 'contraception must be in use for at least one full cycle prior to Baseline. Highly', 'effective contraceptive methods (with a failure rate less than 1% per year), when used', 'consistently and correctly, includes implants, injectables, combined oral contraceptives,', 'some intrauterine devices (IUDs), sexual abstinence or vasectomized partner.', '9.', 'Male subjects must be surgically sterile or, if sexually active with a female partner of', 'childbearing potential, must agree to use a barrier contraceptive method from', 'Baseline through 180 days after the last dose of study drug.', '9.3.2 Exclusion Criteria', '1.', 'Subjects will be ineligible if, in the opinion of the Investigator, they are unlikely to', 'comply with the study protocol or have a concomitant disease or condition that could', 'interfere with the conduct of the study or potentially put the subject at unacceptable', 'risk.', 'The exclusion criteria (except those related to screening) of protocol HZNP-TEP-301 also', 'apply to this open-label extension study.', '9.3.3', 'Removal of Subjects from Therapy or Assessment', 'When the Investigator considers treatment is to be complete, subjects will have an EOT Visit', '3', 'weeks after the final infusion and -undergo the scheduled Week 24 EOT -assessments. Subjects', 'who relapsed during the HZNP TEP 301 study will be discharged after completion of the Week', '24 EOT assessments.', 'nly SSubjects who were proptosis non-responders in HZNP-TEP-301 will participate in the', 'Follow-Up Period. Subjects who enter the Follow-Up Period but prematurely discontinue study', 'participation prior to Month 12 will return for a final visit and undergo the scheduled', 'Month 12/EOS assessments prior to study discharge. Subjects who discontinue due to an AE', 'should be followed until resolution or stabilization of the AE, or an adequate explanation for the', 'event is obtained.', 'Subjects who relapsed during the HZNP-TEP-301 study will not participate in the Follow-up', 'Period. be discharged after completion of the EOT assessments.', 'Subjects who complete the study (Month 12 Visit for proptosis non-responders in Study', 'HZNP-TEP-301 and Week 24 Visit for subjects who relapsed during the Follow-up Period', 'in Study HZNP-TEP-301) will be contacted 6 and 12 months after the last visit via phone', 'or email by research staff to enquire if any treatment for TED has been received since last', 'study contact.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 19 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '9.3.4', 'Criteria for Responders Who Relapse', 'If subjects met the response criteria at Week 24 of HZNP-TEP-301 but subsequently experience', 'a disease relapse during the 48-week Follow-Up Period of the lead-in study, they will have the', 'option to enter this open-label extension study (HZNP-TEP-302) and receive up to 8 infusions of', 'teprotumumab. The criteria to determine relapse is the following:', 'Increase in proptosis of > 2 mm in the study eye since Week 24 of HZNP-TEP-301, or', 'An increase in CAS of > 2 points since Week 24 with an absolute CAS of > 4 in the', 'study eve following Week 24 of HZNP-TEP-301.', 'In addition to one of the bullet points above, the Investigator should also consider the', \"subject's symptomology to ensure a relapse has occurred (e.g., new onset of double\", 'vision).', '9.4.1', 'Treatments Administered', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff.', 'Subjects will receive up to 8 infusions of teprotumumab (10 mg/kg on Day 1 followed by', '20 mg/kg q3W for the remaining infusions) in an open-label fashion; the number of infusions', \"will be determined by the Investigator' clinical judgment.\", 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability', '(see Section 9.4.6.3.2 for details). The first and second infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes). Subsequent infusions will be', 'administered over approximately 60 minutes (but not less than 50 minutes), period providing', 'there are no significant infusion-associated events.', '9.4.6.2 Determination of Dose Volume', 'The volume of study drug to be administered will be determined by the electronic data capture', \"(EDC) interactive web response system (IWRS) and will be based on the subject's weight. The\", 'first dose will be 10 mg/kg, and subsequent doses will be 20 mg/kg. Weight will be measured on', 'Day 1 and Weeks 12 and 24 during the Treatment Period. The dose on Day 1 may be based on', 'the weight determined at the most recent clinic visit, provided the most recent visit was within', 'the prior 3 weeks. The doses on Week 3 through Week 912 will be based on the weight', 'determined on Day 1. The weight used in the Week 12 dose calculation can be the weight', 'determined on Day 1 or the weight obtained at Week 12. The weight obtained at Week 12', 'can be used to adjust the dose beginning at Week 12 or Week 15 through Week 21, and the', 'doses on Weeks 18 through 21 may be adjusted based on the weight obtained at Week 12, as', 'appropriate.', '9.4.6.3.1 Preparation and Administration of Teprotumumab', 'The first and second IV infusions on Day 1 and Week 3 will be administered over', 'approximately 90 minutes (but not less than 80 minutes) for all subjects; subsequent infusions', 'may be administered over a shorter time period (approximately 60 minutes, but not less than', '50 minutes) in the absence of any infusion-associated events. All subjects will be monitored for', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 20 of 118']\n\n###\n\n", "completion": "END"}